NOVAVAX INC Operating Lease, Expense
NOVAVAX INC (NVAX) reported Operating Lease, Expense of $24.20 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2023-11-09
- NOVAVAX INC operating lease, expense for the quarter ending 2022-09-30 was $24.20M, a 450.00% increase year-over-year.
- NOVAVAX INC operating lease, expense for the quarter ending 2022-06-30 was $9.40M, a 17.54% decline year-over-year.
- NOVAVAX INC operating lease, expense for the quarter ending 2022-03-31 was $10.40M, a 940.00% increase year-over-year.
- NOVAVAX INC operating lease, expense for the quarter ending 2021-09-30 was $4.40M, a 97.65% decline year-over-year.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month |
|---|---|---|---|---|
| 2022-09-30 | $24.20M 10-Q · filed 2023-11-09 | $33.60M derived: sum of 2 quarters · filed 2023-11-09 | $44.00M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $9.40M 10-Q · filed 2023-08-08 | $19.80M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $10.40M 10-Q · filed 2023-05-09 | |||
| 2021-09-30 | $4.40M 10-Q · filed 2022-11-09 | $15.80M derived: sum of 2 quarters · filed 2022-11-09 | $17.10M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $11.40M 10-Q · filed 2022-08-09 | $12.40M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $1.00M 10-Q · filed 2022-05-10 | |||
| 2020-09-30 | $187.20M 10-Q · filed 2021-11-05 | $16.00K 10-Q · filed 2020-11-10 | $187.20M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |